- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01291875
Periodontal Treatment and Metabolic Control in Type 2 Diabetic Patients
The studies that correlate periodontal disease (PD) and diabetes mellitus (DM) suggest that individuals with poor glycemic control are at increased risk for developing infections. Despite being controlled for other important risk factors, diabetic patients are three times more likely to develop PD, and therefore, periodontitis has been proposed as the sixth complication of DM.
Besides the effect of diabetes on DP, the reverse has also been studied over the past 15 years, through the idea that chronic and acute infections can directly affect the tissue resistance to insulin. Recent studies have provided evidence that controlling periodontal infection has an impact on improvement of glycemic control in diabetes mellitus patients. The vascularity of the inflamed periodontal tissue serves as a gateway to inflammatory mediators, pathogenic bacteria and their products into the bloodstream. Some researchers have suggested that periodontal treatment in type 2 diabetes mellitus (DMT2) patients, results in beneficial effect on the level of glycemic control. However, there is no conclusive evidence to support this hypothesis.
This research project aims to determinate the impact of periodontal therapy on metabolic control in DMT2 individuals, and determinate the possible association between periodontal disease and DMT2. For the HbA1c outcome this clinical trial had a sample size calculation estimated at 120 patients. For the inflammatory serum markers this study had a sample size estimated at 22 individuals. Blood samples will be collected for evaluation of Hba1c and inflammatory serum markers. This data will highlight the possible role of periodontal therapy on DMT2 metabolic control.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
São Paulo, Brazilië, 05508-900
- School of Dentistry - University of São Paulo
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject aged over 30 years old
- Subject diagnosed with T2DM
- Subject consenting to the study
- Subject with signs of severe periodontitis (at least 50 periodontal pockets, PPD > 4mm and Bleeding on Probing)
Exclusion Criteria:
- Pregnancy - Lactation
- Subject is on chronic treatment (i.e., two weeks or more) with specific medications known to affect periodontal status (phenytoin or cyclosporine) within one month of baseline visit
- Subject with known HIV or Hepatitis (B, C)
- Subjects with uncontrolled systemic diseases (cardiovascular diseases including hypertension, liver, pulmonary diseases, end stage renal failure) and/or neoplasm
- Subjects not capable to provide informed consent
- Subjects on chronic antibiotic therapy or who require antibiotic coverage for periodontal procedures
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Intensive periodontal treatment
|
Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days).
Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted.
After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
|
Actieve vergelijker: Supragingival biofilm control
|
Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Changes in HbA1c and serum inflammatory markers of inflammation after periodontal intervention
Tijdsspanne: It will be assessed 2, 6 and 12 months after periodontal treatment
|
It will be assessed 2, 6 and 12 months after periodontal treatment
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 127/2009
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes mellitus type 2
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationWervingDiabetes mellitus type 2 met complicatiesIndië
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Voltooid
-
AstraZenecaWerving
-
Daewoong Pharmaceutical Co. LTD.Nog niet aan het wervenT2DM (diabetes mellitus type 2)
-
Zhongda HospitalWervingDiabetes mellitus type 2 (T2DM)China
-
Newsoara Biopharma Co., Ltd.WervingT2DM (diabetes mellitus type 2)China
-
Shanghai Golden Leaf MedTec Co. LtdActief, niet wervendDiabetes mellitus type 2 (T2DM)China
-
SanofiVoltooid
-
Haisco Pharmaceutical Group Co., Ltd.VoltooidT2DM (diabetes mellitus type 2)China
Klinische onderzoeken op non-surgical periodontal treatment
-
Hartford HospitalAstellas Pharma IncBeëindigdVerzakking van het bekkenorgaanVerenigde Staten